Legend Biotech (LEGN) FCF Margin (2019 - 2026)
Legend Biotech's (LEGN) quarterly FCF Margin came in at 30.35% in Q1 2026, up 2380.0% YoY from 1.22% in Q1 2025, and down 662.0% on a QoQ basis from 3.98% in Q4 2025.
Powered by 
Analysis
Legend Biotech (LEGN) FCF Margin (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of FCF Margin data on file, last reported at 30.35% in Q1 2026.
- Quarterly FCF Margin rose 2380.0% year-over-year to 30.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.23% (up 3382.0% YoY) and the FY2025 annual result came in at 9.74%, up 1547.0% from the prior year.
- FCF Margin eased to 30.35% in Q1 2026, from 3.98% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 94.39% in Q2 2022 to a low of 371.37% in Q1 2023.
- A 5-year average of 67.71% and a median of 47.56% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin plunged 22889 bps — and 2024, when it surged 39452 bps.
- Tracing LEGN's FCF Margin over 5 years: stood at 104.28% in 2022, then soared by 100 bps to 0.17% in 2023, then sank by 34880 bps to 57.87% in 2024, then soared by 93 bps to 3.98% in 2025, then plunged by 662 bps to 30.35% in 2026.
- The last three FCF Margin figures came in at 30.35% (Q1 2026), 3.98% (Q4 2025), and 12.41% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -3.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.46% |
| Mar 31, 2026 | -25.43% |
| Dec 31, 2025 | 0.06% |
| Sep 30, 2025 | 12.42% |
| Jun 30, 2025 | -1.57% |
| Mar 31, 2025 | -52.10% |
| Dec 31, 2024 | -42.75% |
| Sep 30, 2024 | -46.04% |
| Jun 30, 2024 | 0.95% |
| Mar 31, 2024 | 23.15% |
| Dec 31, 2023 | -114.87% |
| Sep 30, 2023 | -57.77% |
| Jun 30, 2023 | -124.75% |
| Mar 31, 2023 | -371.37% |
| Dec 31, 2022 | -104.28% |
| Sep 30, 2022 | -254.14% |
| Jun 30, 2022 | -8.87% |
| Mar 31, 2022 | -133.03% |
| Dec 31, 2021 | -400.74% |
| Sep 30, 2021 | -196.14% |